Wider utilization of overdose reversal drugs could go a long way in reducing the impact of the opioid epidemic, North Texas experts say. So could responsible prescribing and more use of the state’s prescription monitoring program, which collects and monitors data related to Schedule II, III, IV, and V controlled substances. “Responsible prescribing is one of the cornerstones of addressing the issue,” said Glenn Hardesty, an emergency medicine physician with Texas Health Resources and opioid expert. He said that changes in the approach to prescribing opiates have already curbed access to the legally obtained drugs. He added that building the… Full Story
I missed this a couple weeks ago, but I found it to be a well-reasoned writing approach to a very important topic, so I wanted to pass it along. Dr. Carl Noe, medical director at the Eugene McDermott Center for Pain Management at UT Southwestern Medical Center, takes on the topics of potential alternatives to prescribing opioids for chronic pain. Here’s Noe: But the convenience of offering a prescription for quick relief won over doctors, and our country’s pill culture appeals to patients. We in the medical community should have known better. There’s no scientific data to show that opioids… Full Story
Law firms are reaching out to public officials across Texas in an effort to win the right to sue big pharmaceutical companies over opioids on their behalf, the Texas Tribune reported this week. The Trib’s report follows news of various other municipalities, including Dallas, filing suit against big pharma over the opioid crisis. More than 1,100 Texas died from opioids in 2016. The Trib‘s story starts with an anecdote from Collin County, where County Administrator Bill Bilyeu has resorted to tuning out the incessant requests, which he says aren’t tailored to Collin County’s needs.
The Texas Tech University Health Sciences Center School of Pharmacy will move all four years of its program to Dallas-Fort Worth. The area has been home to years three and four since 1999, including partnering with 240 hospitals, clinics, and pharmacies. But students have traditionally had to move to Amarillo, Abilene, or Lubbock for their first two years. About half of the program’s enrollment comes from DFW and surrounding areas, but TTUHSC President Tedd Mitchell said in a statement that qualified candidates have been left on the table due to their inability to relocate. “So bringing all four years of… Full Story
Walgreens executives have approached AmerisourceBergen Corp. about a buyout, according to a scoop from the Wall Street Journal citing people familiar with the matter. The drug distributor Amerisource is building a 300,000-square-foot regional headquarters in Carrollton that could eventually house as many as 3,000 employees, so there’s potential for local impact here. Walgreens already owns about a quarter of the company. The Carrollton facility is set to reach completion this year, and a good portion of the first 1,200 move-ins will come from Amerisource’s current offices in Frisco as the company consolidates its North Texas presence. I’ve reached out to… Full Story
The time is now: D CEO and D CEO Healthcare have opened nominations for their fourth annual Excellence in Healthcare awards feature. Full Story
San Francisco-based McKesson Corp., a retail pharmaceutical distributor that also provides health information technology, medical supplies, and care management tools, recently opened a new campus in Las Colinas. Full Story
Pharmaceutical giant Novartis International is scooping up Fort Worth-based Encore Vision as it aims to introduce the market’s first topical treatment of the eye condition presbyopia.
Novartis, a Swiss public company that raked in $49.4 billion in revenue last year, announced the agreement Tuesday, but did not disclose the financial terms. Full Story
The deal comes after North Texas suffered one of its worst second quarters for venture capital investment in recordable history. Full Story
Pharmaceutical giant Pfizer is suing the Texas Health and Human Services Commission over allegations that it turned over Medicaid prescription data that was proprietary. Full Story